Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Recruiting · NCT06625970 · Registry updated 2026-07-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-07-31 | NCT06625970 |
2 results · Page 1 of 1
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Georges Francois Leclerc | Dijon | France | 11 |
| CHU Martinique | Fort-de-France | Martinique | 1 |
| CHU Saint-Etienne | Saint-Etienne | France | 22 |
| Clinique Pasteur Lanroze - Brest | Brest | France | 1 |
| Groupe Hospitalier Paris Saint-Joseph | Paris | France | 3 |
| Gustave Roussy, Cancer Campus, Grand Paris | Villejuif | France | 2 |